Her-2、EGFR、PS-2、ER在乳腺癌中的表达及其临床意义

目的 探讨人表皮生长因子受体2（Her-2）、表皮生长因子受体（EGFR）、雌激素调节蛋白（PS-2）、雌激素受体（ER）在乳腺癌中的表达及其临床意义。方法 用免疫组织化学方法检测108例乳腺癌患者Her-2、EGFR、PS-2、ER的表达情况，并进行比较。结果 Her-2、EGFR、PS-2、ER表达阳性者分别为40例（37．0％）、44例（40、7％）、62例（57．4％）和58例（53．7％）。Her-2的表达与EGFR无相关性（p0．05），与PS-2呈负相关（P〈0．05），与ER呈负相关（P〈0．05）。Her-2、EGFR、PS-2、ER表达与乳腺癌的组织学分级相关（P〈0．05）。Her-2、EGFR、ER表达与淋巴结转移相关（P〈0、05），Her-2、EGFR、PS．2、ER与乳腺癌的病理学类型、患者年龄及肿瘤大小无关（P〉0、05）。结论 乳腺癌中Her-2、EGFR表达提示患者预后不良；PS．2、ER表达提示患者预后良好；Her-2、EGFR、PS．2、ER是判断乳腺癌预后的有效指标。

Expressions of Her-2, EGFR, PS-2 and ER in breast cancer and their clinical implications

Objective To detect the expressions of human epidermal growth factor receptor 2 (Her-2), epidermal growth factor receptor (EGFR), presenilin 2 (PS-2) and estrogen receptor (ER) in breast cancer and discuss their clinical implications. Methods The expressions of Her-2, EGFR, PS-2 and ER were measured immunohistochemically in 108 patients with breast cancer. Results The positive expression rates of Her-2, EGFR, PS-2 and ER were 37.0%, 40.7%, 57.4% and 53.7% respectively in the breast cancer patients. The expression of Her-2 was not correlated with EGFR, but inversely correlated with PS-2 and ER. The expressions of Her-2 and EGFR, PS-2, ER were correlated with the histological grades (P<0.05), and Her-2, EGFR and ER expressions with lymph node metastasis (P<0.05). The expressions of Her-2, EGFR, PS-2 and ER did not correlate to the pathological types, patient's age and tumor size (P>0.05). Conclusion Expressions of Her-2 and EGFR often suggests an unfavorable prognosis while expressions of PS-2 and ER suggest a more favorable one. Expressions of Her-2, EGFR, PS-2 and ER are useful prognostic factors in breast cancer patients.